204 related articles for article (PubMed ID: 33809455)
1. NFκB-Activated COX2/PGE
Ibrahim OM; Basse PH; Jiang W; Guru K; Chatta G; Kalinski P
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809455
[TBL] [Abstract][Full Text] [Related]
2. Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction.
Muthuswamy R; Wang L; Pitteroff J; Gingrich JR; Kalinski P
J Immunother Cancer; 2015; 3():6. PubMed ID: 25806105
[TBL] [Abstract][Full Text] [Related]
3. Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment.
Theodoraki MN; Yerneni S; Sarkar SN; Orr B; Muthuswamy R; Voyten J; Modugno F; Jiang W; Grimm M; Basse PH; Bartlett DL; Edwards RP; Kalinski P
Cancer Res; 2018 Aug; 78(15):4292-4302. PubMed ID: 29853604
[TBL] [Abstract][Full Text] [Related]
4. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.
Muthuswamy R; Corman JM; Dahl K; Chatta GS; Kalinski P
Prostate; 2016 Sep; 76(12):1095-105. PubMed ID: 27199259
[TBL] [Abstract][Full Text] [Related]
5. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.
Obermajer N; Muthuswamy R; Lesnock J; Edwards RP; Kalinski P
Blood; 2011 Nov; 118(20):5498-505. PubMed ID: 21972293
[TBL] [Abstract][Full Text] [Related]
6. Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx.
Gandhi S; Opyrchal M; Grimm MJ; Slomba RT; Kokolus KM; Witkiewicz A; Attwood K; Groman A; Williams L; Tarquini ML; Wallace PK; Soh KT; Minderman H; Maguire O; O'Connor TL; Early AP; Levine EG; Kalinski P
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37963636
[TBL] [Abstract][Full Text] [Related]
7. Role of tumor microenvironment in the efficacy of BCG therapy.
Ibrahim OM; Pandey RK; Chatta G; Kalinski P
Trends Res; 2020 Oct; 3(4):. PubMed ID: 33178990
[TBL] [Abstract][Full Text] [Related]
8. Histamine and prostaglandin E up-regulate the production of Th2-attracting chemokines (CCL17 and CCL22) and down-regulate IFN-gamma-induced CXCL10 production by immature human dendritic cells.
McIlroy A; Caron G; Blanchard S; Frémaux I; Duluc D; Delneste Y; Chevailler A; Jeannin P
Immunology; 2006 Apr; 117(4):507-16. PubMed ID: 16556265
[TBL] [Abstract][Full Text] [Related]
9. Statins enhance rotator cuff healing by stimulating the COX2/PGE2/EP4 pathway: an in vivo and in vitro study.
Dolkart O; Liron T; Chechik O; Somjen D; Brosh T; Maman E; Gabet Y
Am J Sports Med; 2014 Dec; 42(12):2869-76. PubMed ID: 25184246
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer.
Dovedi SJ; Kirby JA; Atkins H; Davies BR; Kelly JD
J Urol; 2005 Jul; 174(1):332-7; discussion 337. PubMed ID: 15947685
[TBL] [Abstract][Full Text] [Related]
11. CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes.
Liu Y; Wu Y; Zhang P; Xu C; Liu Z; He C; Liu Y; Kang Z
Front Oncol; 2021; 11():636870. PubMed ID: 33747959
[TBL] [Abstract][Full Text] [Related]
12. Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration.
Karavitis J; Hix LM; Shi YH; Schultz RF; Khazaie K; Zhang M
PLoS One; 2012; 7(9):e46342. PubMed ID: 23029485
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Cytokines and Differentiation of Th17 and Treg by Dendritic Cells: Central Role of Prostaglandin E2 Induced by
Liu H; Xiong X; Zhai W; Zhu T; Zhu X; Zhu Y; Peng Y; Zhang Y; Wang J; Chen H; Chen Y; Guo A
Microorganisms; 2020 Jan; 8(2):. PubMed ID: 32023904
[No Abstract] [Full Text] [Related]
14. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action.
Take Y; Koizumi S; Nagahisa A
Front Immunol; 2020; 11():324. PubMed ID: 32210957
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
Dovedi SJ; Kirby JA; Davies BR; Leung H; Kelly JD
Eur Urol; 2008 Sep; 54(3):621-30. PubMed ID: 18222600
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E
Miao J; Lu X; Hu Y; Piao C; Wu X; Liu X; Huang C; Wang Y; Li D; Liu J
Oncotarget; 2017 Oct; 8(52):89802-89810. PubMed ID: 29163789
[TBL] [Abstract][Full Text] [Related]
17. Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer.
Zhong W; Wang B; Yu H; Lin J; Xia K; Hou W; Yang M; Chen J; Yang M; Wang X; Huang J; Lin T
Oncoimmunology; 2020 Jun; 9(1):1776060. PubMed ID: 32923138
[TBL] [Abstract][Full Text] [Related]
18. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity.
Albu DI; Wang Z; Huang KC; Wu J; Twine N; Leacu S; Ingersoll C; Parent L; Lee W; Liu D; Wright-Michaud R; Kumar N; Kuznetsov G; Chen Q; Zheng W; Nomoto K; Woodall-Jappe M; Bao X
Oncoimmunology; 2017; 6(8):e1338239. PubMed ID: 28920002
[TBL] [Abstract][Full Text] [Related]
19. Effect of nitric oxide inhibition in Bacillus Calmette-Guerin bladder cancer treatment.
Langle YV; Balarino NP; Belgorosky D; Cresta Morgado PD; Sandes EO; Marino L; Bilbao ER; Zambrano M; Lodillinsky C; Eiján AM
Nitric Oxide; 2020 May; 98():50-59. PubMed ID: 32147582
[TBL] [Abstract][Full Text] [Related]
20. Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment.
Wong JL; Obermajer N; Odunsi K; Edwards RP; Kalinski P
Cancer Immunol Res; 2016 Apr; 4(4):303-11. PubMed ID: 26817996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
